SOURCE: Revolutions Medical Corp.

Revolutions Medical Corp.

December 17, 2009 07:00 ET

CT Scan Cancer Revelation Makes Need for RevMed's MRI Technology Critical

Fears Could Cause Dramatic Shift to MRI, Overwhelming Existing Radiologist Ranks

CHARLESTON, SC--(Marketwire - December 17, 2009) - Revolutions Medical Corporation ("RevMed" or the "Company") (OTCBB: RMCP), producers of the RevVac safety syringe, RevColor, RevDisplay and Rev3D MRI Technology, announced today that recent mass media reports that CT scans cause cancer could rapidly elevate MRI as the technology of choice for musculoskeletal scans and more. A resulting spike in the number of MRI scans would not be met by an equal increase in the number of radiologists, making the need to arm the existing ranks with enhanced diagnostic tools a critical one.

According to the Archives of Internal Medicine (, radiation from CT scans done in 2007 alone will cause 29,000 cancers (including 2,000 excess breast cancer cases) and kill nearly 15,000 Americans. Read the following major media outlet features:


Wall Street Journal:


"This is nothing short of a bombshell announcement for the MRI industry," stated Revolutions Medical CTO Richard Theriault. "MRI has long been a potential replacement for CT scans across a variety of applications, but CT has been the physicians' choice as the less expensive of the two options. With the very real dangers of CT now exposed, patient safety will likely trump cost concerns. Moreover, as insurance companies evaluate the financial impact of a cancer case vs. a moderately more expensive scan, the math may drive a mandated move to MRI.

"What does this mean for RevMed? The number of radiologists has remained constant in recent years, even as the Baby Boomers age and MRI scan counts are steadily climbing. We are nearing an alarming tipping point where there will be more scans than professionals to read them; add to that a potential immediate and substantial shift from CT to MRI and the possibility for widespread misdiagnoses is a real one. Radiologists need a tool that makes the reading of scans more efficient and intuitive, and increases diagnostic confidence even at a faster pace. The RevMed MRI Technology (RevColor, RevDisplay and Rev3D) could provide exactly that solution. With our ability to convert standard grayscale scans to segmented, three-dimensional, color images we can help radiologists arrive at the correct diagnosis much more quickly, and at less risk to the patient."

To be added to the Revolutions Medical investor email list, please email with RMCP in the subject line.

Become a RevMed fan and follow the Company on Facebook -- visit

About Revolutions Medical Corporation (

RevMed's products include the RevVac safety syringe (FDA approved), safety blood drawing device and safety IV catheter. RevMed also provides RevColor, RevDisplay and Rev3D -- software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software suite's functionality includes sorting of images, color, 3D and automatic segmentation of images.

Investor Resource Center

Fact Sheet:

CEO Ron Wheet Audio Interview:

RevVac Demo Video:


The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact Information